This post was originally published on this site
https://i-invdn-com.akamaized.net/news/World_News_8_M_1440052125.jpg
The proceeds will be used to fund its messenger RNA-vaccine program and expand its in-house manufacturing capacities, the company said.
Earlier this month, CureVac struck an alliance with drugmaker Bayer AG (DE:BAYGN) to help develop its experimental COVID-19 vaccine.
CureVac’s shares fell 3.3% to $101.01 in extended trading on Monday.
The Nasdaq-listed company, which is backed by investors Dietmar Hopp, the Gates Foundation and GlaxoSmithKline (NYSE:GSK) as well as the German government, has said it aims to produce up to 300 million doses of the vaccine in 2021 and up to 600 million in 2022.
